MSI-H/dMMR

P2, N=50, Not yet recruiting, Jonsson Comprehensive Cancer Center

Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.

P2, N=10, Not yet recruiting, Haihua Yuan

Minimal microsatellite shift is commonly detected in MSI-H cases, and some cases are difficult to interpret due to their classification within the equivocal range. Increasing the number of microsatellite loci, combined with visualization graph comparison and integration of mismatch repair protein immunophenotype and histological features, can effectively improve the accuracy of MSI-H interpretation.

ICI rechallenge in GC should be regarded as a biomarker-informed investigational strategy rather than a standard of care. Prospective trials, standardized definitions, validated biomarkers, and careful toxicity monitoring are needed.

YORC presents more often with symptoms and advanced disease (M+, N+, EMVI+), yet short-term survival in non-metastatic patients tended to parallel that of older individuals. These findings underscore the need for earlier diagnosis, tailored management, and increased clinical awareness.

Colorectal cancer treatment is increasingly evolving into a precision oncology approach. Integration of molecular biomarkers enables tailored therapy decisions and opens new options, particularly in adjuvant and metastatic settings.

BRAF and RAS mutation occurred in 60% and 14% of the patients with available molecular data, respectively. No patients harbored HER2 amplification, suggesting that the co-occurrence of HER2 amplification and dMMR/MSI is essentially anecdotal, making therefore HER2 testing in this subgroup less compelling.

P1, N=267, Recruiting, Pfizer | Trial completion date: Aug 2030 --> Oct 2029 | Trial primary completion date: Feb 2029 --> Apr 2028

Molecular classification provides clinically meaningful information beyond traditional histopathologic factors and is closely associated with the risk of lymph-node metastasis in endometrial cancer. The consistently low nodal involvement observed in POLEmut and the high risk observed in p53abn support a more tailored approach to surgical staging.

Results from the RUBY and NRG-GY018 trials show that combining dostarlimab or pembrolizumab with platinum-based chemotherapy improves survival in patients with untreated advanced disease...Overcoming this resistance requires combination strategies, such as using anti-angiogenic agents like lenvatinib with immune checkpoint inhibitors, as shown in the KEYNOTE-775 trial...As molecular monitoring via liquid biopsy and the use of antibody-drug conjugates (ADCs) evolve, the personalization of immunotherapy continues to progress. This review examines current clinical evidence and the mechanisms of resistance to define the future of precision medicine in endometrial cancer.

The complete response to levonorgestrel intra-uterine device therapy was lower than expected for endometrial intra-epithelial neoplasia. Response rates varied by molecular classification, with worse outcomes observed in deficient mismatch repair and p53 abnormal sub-types. Although limited by sample size, these findings suggest that levonorgestrel intra-uterine device therapy may not be sufficient for all molecular sub-groups.